EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema

Sarah Walsh iD, Anja Haltner iD, Meaghan Bartlett iD, John Sears, Yinglei Li, Maebh Kelly, Simona Gavata-Steiger, Chiara Nenci, Iris Jacobs, Ingo Pragst iD, Neelanjana Ray, Imtiaz A Samjoo iD

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2024-0237 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Sarah Walsh und 11 weiteren Autor:innen. Beteiligte Einrichtung: EVERSANA™, Burlington, ON L7N 3H8, Canada. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized, Broadly Neutralizing Antibodies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aimed to estimate the relative efficacy between garadacimab 200 mg once monthly (200 QM) and two dosing regimens of lanadelumab (300 mg once every 2 weeks [300 Q2W] and 300 mg once every 4 weeks [300 Q4W]) in adolescent/adult patients with hereditary angioedema (HAE) using matching-adjusted indirect comparisons (MAICs), in the absence of head-to-head randomized controlled trials. Materials & methods: Individual patient data were available from the phase II ( NCT03712228 ) and the phase III VANGUARD ( NCT04656418 ) trials investigating garadacimab, and published summary-level data from the phase III HELP trial investigating lanadelumab ( NCT02586805 ). The primary outcome was time-normalized number of HAE attacks. Secondary efficacy outcomes included time-normalized number of HAE attacks requiring on-demand treatment, time-normalized number of moderate and/or severe HAE attacks, and proportion of attack-free patients. Quality of life (QoL) was also assessed via change from baseline in AE-QoL total score.

Results

Compared with lanadelumab 300 Q2W, garadacimab 200 QM statistically significantly reduced number of moderate and/or severe HAE attacks (rate ratio [RR]; 95% confidence interval: 0.25; 0.07, 0.84) and improved AE-QoL score (mean difference: -17.38; -33.67, -1.08). Compared with lanadelumab 300 Q4W, garadacimab 200 QM showed statistically significant improvements in all outcomes: HAE attacks (RR: 0.29; 0.13, 0.63), attacks requiring on-demand treatment (RR: 0.29; 0.13, 0.66), moderate and/or severe HAE attacks (RR: 0.15; 0.05, 0.49), proportion of attack-free patients (hazard ratio: 3.25; 1.45, 7.29), and AE-QoL score (mean difference: -21.29; -37.39, -5.18).

Conclusion

These MAICs showed improved efficacy and QoL with garadacimab compared with lanadelumab across multiple endpoints. These findings demonstrate that garadacimab may provide improved therapeutic benefit compared with lanadelumab in the long-term prophylactic treatment of patients with HAE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryAntibodies, Monoclonal, HumanizedBroadly Neutralizing AntibodiesHumansAdultMaleAdolescentFemaleYoung AdultMiddle AgedTreatment OutcomeDrug Administration ScheduleQuality of Life

Stichwörter der Autor:innen

comparative evidencegaradacimabhereditary angioedemamatching-adjusted indirect comparison

Substanzen

Antibodies, Monoclonal, HumanizedlanadelumabBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • EVERSANA™, Burlington, ON L7N 3H8, Canada.
  • EVERSANA™, New York, NY 10018, USA.
  • CSL Behring, King of Prussia, PA 19406, USA.
  • CSL Behring Ltd, Haywards Heath, UK.
  • CSL Behring AG, Bern, Switzerland.
  • CSL Behring GmbH, Marburg, Germany.

ORCID-Profile: Sarah Walsh, Anja Haltner, Meaghan Bartlett, Ingo Pragst, Imtiaz A Samjoo

Zitieren

APA

Walsh, S., Haltner, A., Bartlett, M., Sears, J., Li, Y., Kelly, M., Gavata-Steiger, S., Nenci, C., Jacobs, I., Pragst, I., Ray, N., & Samjoo, I. A. (2025). Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0237

Vancouver

Walsh S, Haltner A, Bartlett M, Sears J, Li Y, Kelly M, et al. Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0237

BibTeX
@article{Walsh2025,
  author = {Walsh, Sarah and Haltner, Anja and Bartlett, Meaghan and Sears, John and Li, Yinglei and Kelly, Maebh and Gavata-Steiger, Simona and Nenci, Chiara and Jacobs, Iris and Pragst, Ingo and Ray, Neelanjana and Samjoo, Imtiaz A},
  title = {Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0237}
}
Kostenlos starten →